Turtlemint Fintech Solutions Files Confidential DRHP for IPO

16 September 2025
1 min read
Turtlemint Fintech Solutions Files Confidential DRHP for IPO
whatsapp
facebook
twitter
linkedin
telegram
copyToClipboard

Turtlemint Fintech Solutions, the insurtech company headquartered in Mumbai, has filed a confidential draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for its initial public offering (IPO). 

The company has chosen a confidential pre-filing route as per its public announcement on September 4, 2025. 

The promoters of the company are its founders Dhirendra Mahyavanshi and Anand Prabhudesai. 

Turtlemint Fintech Solutions IPO Details

Here are the details so far:

  • The company has filed a confidential DRHP with the SEBI. 
  • It has taken the confidential pre-filing route that has been chosen by several other firms like Tata Capital, Swiggy, Shadowfax, PhysicsWallah and Shiprocket recently. 
  • The lead bankers include ICICI Securities and Jefferies India. 
  • The company has issued a clarification that the filing does not necessarily confirm that an IPO will follow soon.

Check out newly Listed IPOs on BSE and NSE.

About Turtlemint Fintech Solutions 

Incorporated in 2015, Turtlemint Fintech Solutions is a leading technology-driven intermediary connecting customers, insurers and insurance advisors. It works to distribute health, life and motor insurance products, while enabling access to mutual funds, loans and other financial products on its platform. 

The company has sold 1.6 crore policies over 19,105 pin codes via a network of 400,000+ POS (point of sale) persons for FY2023-25. It also has partnerships with 430,000+ trained insurance advisors and more than 42 insurer partners, thereby simplifying insurance purchases for end-users. It is backed by PE firms like Nexus Venture Partners, Peak XV, Jungle Ventures, Amansa Capital and others. 

Explore other Upcoming IPOs on BSE and NSE.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. 

To read the RA disclaimer, please click here.

Do you like this edition?